Related Experiment Videos
Venous thrombosis and rifampicin
1Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa.
Abstract:
In a retrospective analysis of clinically diagnosed and lower limb deep vein thrombosis (DVT) proven by contrast venography, DVT complicated admissions in 46 (3.4%) of 1366 adult patients treated in a tuberculosis hospital during 1986. Analysis of 7542 admissions during 1978-86 showed a relative risk of 4.74 in patients treated with regimens including rifampicin compared with other regimens. DVT was significantly more common in winter months and usually occurred within 2 weeks of treatment being started. This probable association between rifampicin and DVT does not contraindicate use of this drug, but measures to prevent DVT should be taken in inpatients receiving rifampicin.
Insights
Rifampicin, an antibiotic for tuberculosis, may increase the risk of deep vein thrombosis (DVT). This study found a higher DVT incidence in patients receiving rifampicin, suggesting preventive measures for inpatients.
Area of Science:
- Medical Research
- Pharmacology
- Public Health
Background:
- Deep vein thrombosis (DVT) is a serious condition often associated with hospitalization.
- Tuberculosis treatment regimens can influence patient outcomes and complication risks.
Purpose of the Study:
- To investigate the association between rifampicin use and the incidence of deep vein thrombosis (DVT) in tuberculosis patients.
- To identify risk factors and temporal patterns of DVT in this patient population.
Main Methods:
- Retrospective analysis of 1366 adult patients admitted to a tuberculosis hospital between 1978 and 1986.
- DVT diagnosis confirmed by contrast venography.
- Comparison of DVT incidence in patients receiving rifampicin-containing regimens versus other treatments.
Main Results:
- Deep vein thrombosis (DVT) complicated 3.4% of admissions.
- Patients treated with rifampicin had a 4.74 times higher relative risk of DVT compared to those on other regimens.
- DVT was more frequent in winter and typically occurred within two weeks of starting treatment.
Conclusions:
- A probable association exists between rifampicin and deep vein thrombosis (DVT).
- Rifampicin use should not be contraindicated solely based on this association.
- Preventive measures against DVT are recommended for inpatients receiving rifampicin.